ArticleACS omega2025
Mechanism of Luteolin in the Treatment of Primary Sjogren's Syndrome: a Study Based on Systems Biology and Cell Experiments.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms of Chinese Medicines for Primary Sjögren's Syndrome: A Review.Chinese journal of integrative medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrimary Sjogren's Syndrome (pSS) is a chronic inflammatory autoimmune disease that manifests as dry mouth and eyes. Luteolin can repress immuno-inflammation and improve the function of exocrine glands.
methodsBibliometrics was used to visualize pSS-related key indicators. The efficacy of traditional Chinese medicines (TCMs) in pSS treatment was analyzed with the internal database containing the clinical records of pSS. Using the network pharmacology technology to identify involved pathways. Additionally, molecular docking and cell experiments were performed to screen and verify the therapeutic effect of luteolin on pSS.
resultsKey indicators that were selected according to the bibliometrics were worse in pSS and had certain compatibility and correlation with laboratory and immunoinflammatory indicators. After treatment, pSS patients showed improvements in the above indicators. The results of risk analyses revealed that TCMs were protective factors for laboratory indicators and key indicators. The main effective TCMs for pSS treatment and TNF pathways were identified with network pharmacology. Cell experiments validated that luteolin indeed improved the secretion dysfunction and inflammation of modeled human submandibular gland epithelial cells through the TNF/NF-κB pathway.
conclusionsTCMs may effectively improve transcription factors and immuno-inflammatory markers in pSS patients. Moreover, we hypothesized and verified the potential mechanism of action of luteolin in HSG cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.